膜性肾病:将基础科学整合到改进的临床管理中
本文综述特发性膜性肾病的自身免疫机制,包括抗磷脂酶A2受体(PLA2R)抗体(占70%~75%病例)和抗THSD7A抗体,讨论抗体检测如何改变原发性/自身免疫性膜性肾病的诊断、预后和治疗,并展望创新疗法。
要点
- 抗PLA2R抗体以IgG4亚型为主,可用酶联免疫吸附试验定量检测,辅助诊断并监测免疫抑制治疗反应。
- 2014年发现第二个自身抗原THSD7A;活检免疫染色可在5%~10%血清抗体阴性病例的沉积免疫复合物中检出PLA2R或THSD7A抗原。
- 建议用原发性或自身免疫性膜性肾病(AMN)取代特发性膜性肾病(IMN)这一术语,涵盖既往约80%~90%的IMN病例。
核心结论
- 对自身免疫机制的认识及序贯检测这些自身抗体,可能通过更精确地定义诊断、预后和治疗,改变自身免疫性膜性肾病(AMN)的临床管理与病程轨迹。
研究设计与样本
- 本文为综述,围绕特发性膜性肾病(INM)的自身免疫机制、自身抗体检测及临床管理进行讨论。
主要发现
- 2009年明确IMN的自身免疫性质,70%~75%病例的肾小球沉积IgG针对足细胞受体磷脂酶A2受体(PLA2R)。
- 抗PLA2R自身抗体以IgG4亚型为主,已用酶联免疫吸附试验在血清中定量,用于辅助诊断和监测免疫抑制治疗反应。
- 2014年发现第二个自身抗原THSD7A;活检免疫染色在5%~10%血清抗体阴性病例的沉积免疫复合物中检出PLA2R或THSD7A抗原。
- 原发性或自身免疫性膜性肾病(抗PLA2R或抗THSD7A阳性)涵盖既往约80%~90%的IMN病例;继发性膜性肾病与这些自身抗体的关联低得多,但其在继发性病例中的真实发生率仍需明确。
关键数值与推荐
- 抗PLA2R抗体见于70%~75%的IMN病例。
- 活检免疫染色在5%~10%血清抗体阴性病例的沉积免疫复合物中检出PLA2R或THSD7A抗原。
- 原发性或自身免疫性膜性肾病(抗PLA2R或抗THSD7A阳性)涵盖既往约80%~90%的IMN病例。
临床怎么用
- 在疾病病程早期应用这些自身抗体检测于新旧疗法,将为AMN管理提供额外精确性。
- 文中讨论了创新治疗方法,预期将实现改善A(I)MN患者护理的最终目标。
局限性
- 继发性膜性肾病与这些自身抗体的关联低得多,但其在继发性病例中的真实发生率仍需明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic membranous nephropathy (INM) remains a common cause of the nephrotic syndrome in adults. The autoimmune nature of IMN was clearly delineated in 2009 with the identification of the glomerular-deposited IgG to be a podocyte receptor, phospholipase A2 receptor (PLA2R) in 70% to 75% of cases. This anti-PLA2R autoantibody, predominantly the IgG4 subclass, has been quantitated in serum using an enzyme-linked immunosorbent assay and has been used to aid diagnosis and monitor response to immunosuppressive therapy. In 2014, a second autoantigen, thrombospondin type 1 domain-containing 7A (THSD7A), was identified. Immunostaining of biopsy specimens has further detected either PLA2R or THSD7A antigen in the deposited immune complexes in 5% to 10% of cases autoantibody seronegative at the time of biopsy. Therefore, the term IMN should now be superseded by the term primary or autoimmune MN (AMN) (anti-PLA2R or anti-THSD7A positive) classifying ∼80% to 90% of cases previously designated IMN. Cases of secondary MN associated with other diseases show much lower association with these autoantibodies, but their true incidence in secondary cases still needs to be defined. How knowledge of the autoimmune mechanism and the sequential measurement of these autoantibodies is likely to change the clinical management and trajectory of AMN by more precisely defining its diagnosis, prognosis, and treatment is discussed. Their application early in the disease course to new and old therapies will provide additional precision to AMN management. We also review innovative therapeutic approaches on the horizon that are expected to lead to our ultimate goal of improved patient care in A(I)MN.
引用
- Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017. PMID: 28065518. doi:10.1016/j.kint.2016.09.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。